Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 0.70 is 683% above its 5-year average of -0.12, near the high end of its 5-year range (-1.02–0.85).
4.76% below its 12-month average of 0.73.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.17.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T13:25:16.481Z. Historical observations retain their original dates. Historical series through 2026-10-05.
EARNINGS PER SHARE (EPS)
0.70
EARNINGS PER SHARE (EPS) AVG TTM
0.73
EARNINGS PER SHARE (EPS) AVG 3Y
0.23
EARNINGS PER SHARE (EPS) AVG 5Y
-0.12
EARNINGS PER SHARE (EPS) AVG 10Y
-0.77
EARNINGS PER SHARE (EPS) AVG 15Y
-0.94
EARNINGS PER SHARE (EPS) AVG 20Y
-0.88
CURRENT VS TTM AVG
-4.76%
CURRENT VS 3Y AVG
+207.69%
CURRENT VS 5Y AVG
+683.33%
CURRENT VS 10Y AVG
+190.91%
CURRENT VS 15Y AVG
+174.68%
CURRENT VS 20Y AVG
+179.61%
ADMA Biologics, Inc.
Market Cap
$2.34B
Earnings Per Share (EPS)
0.70
TTM Avg
0.73
3Y Avg
0.23
5Y Avg
-0.12
Market Cap
$2.31B
Earnings Per Share (EPS)
3.08
TTM Avg
2.66
3Y Avg
2.64
5Y Avg
2.23
Market Cap
$2.43B
Earnings Per Share (EPS)
-0.04
TTM Avg
-0.13
3Y Avg
-0.35
5Y Avg
-0.53
Market Cap
$2.43B
Earnings Per Share (EPS)
-6.60
TTM Avg
-4.98
3Y Avg
-14.61
5Y Avg
-21.72
Market Cap
$2.51B
Earnings Per Share (EPS)
-1.04
TTM Avg
-1.56
3Y Avg
-1.52
5Y Avg
-1.27
Market Cap
$2.17B
Earnings Per Share (EPS)
-4.36
TTM Avg
-3.17
3Y Avg
-2.92
5Y Avg
-2.56
Market Cap
$2.11B
Earnings Per Share (EPS)
5.70
TTM Avg
4.76
3Y Avg
4.08
5Y Avg
3.55
Market Cap
$2.06B
Earnings Per Share (EPS)
-1.50
TTM Avg
0.42
3Y Avg
-0.42
5Y Avg
-0.63
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | $2.34B | 0.70 | 0.73 | 0.23 | -0.12 |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.31B | 3.08 | 2.66 | 2.64 | 2.23 |
| Clover Health Investments, Corp. (CLOV)vs › | $2.43B | -0.04 | -0.13 | -0.35 | -0.53 |
| Disc Medicine, Inc. (IRON)vs › | $2.43B | -6.60 | -4.98 | -14.61 | -21.72 |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.51B | -1.04 | -1.56 | -1.52 | -1.27 |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.17B | -4.36 | -3.17 | -2.92 | -2.56 |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 5.70 | 4.76 | 4.08 | 3.55 |
| Alvotech (ALVO)vs › | $2.07B | -0.63 | -0.39 | -1.45 | -2.42 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.06B | -1.50 | 0.42 | -0.42 | -0.63 |
| Beam Therapeutics Inc. (BEAM)vs › | $2.64B | -0.86 | -2.70 | -2.81 | -3.40 |
Trailing EPS (TTM)
$0.70
Forward EPS (Est.)
$0.80
P/E Ratio
14.4
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 0.62 |
| 2024-12-31 | 0.85 |
| 2023-12-31 | -0.13 |
| 2022-12-31 | -0.43 |
| 2021-12-31 | -0.61 |
| 2020-12-31 | -1.02 |
| 2019-12-31 | -1.05 |
| 2018-12-31 | -1.45 |
| 2017-12-31 | -1.91 |
| 2016-12-31 | -1.61 |
| 2015-12-31 | -1.73 |
| 2014-12-31 | -1.81 |
| 2013-12-31 | -2.38 |
| 2012-12-31 | -1.39 |
| 2011-06-30 | -0.01 |
| 2010-06-30 | -0.01 |
| 2009-06-30 | -8.00 |
| 2008-06-30 | -9956.40 |
| 2007-06-30 | -11.87 |
